Clinical trials show small reductions in total cholesterol, LDL cholesterol, and triglycerides alongside their primary metabolic benefits
"Zepbound (tirzepatide) Label Information." Garvey WT, et al
Metabolic effects of a growth hormone-releasing factor in patients with HIV
It has to be making sure fewer people ever need to ask it in the first place
MsrA catalyzes the reduction of the S-form of methionine sulfoxide
Selective SGLT1 inhibition in the early intestine results in increased glucose delivery to the distal intestine and colon [29,30,31,32], where it reduces colonic pH and is metabolized by the gut microbiome, resulting in an increase in short chain fatty acids (SCFA) [33]